All Articles

As Hasbro opens a massive new Wizards of the Coast studio in Montréal, the move signals a strategic shift toward in-house digital gaming amid industry turbulence.

As AI data centers strain the global grid, Alsym Energy's non-flammable sodium-ion batteries offer a radical, passive-cooling solution to power the future.

As the AI boom fuels demand for advanced chips, Fujifilm is expanding its U.S. manufacturing and pioneering PFAS-free materials for next-generation fabs.

As regulatory scrutiny forces legacy proptech to retreat, a new generation of revenue intelligence is targeting commercial real estate's riskiest phase.

With a record $30.6 million backlog and a "no rip-and-replace" software strategy, Airship AI is rewriting the playbook for edge intelligence and federal tech.

As Broadcom reshapes the VMware ecosystem, IBM is shedding legacy workloads. Enter 11:11 Systems, the PE-backed aggregator quietly rolling up the cloud.

Control AV appoints Kevin Cartier as COO and opens an Orlando office, bridging the gap between cruise ships and theme parks in a rapidly converging industry.

Consumers are handing off daily errands to autonomous AI agents despite deep privacy fears. Here is why utility is trumping trust in the new economy.

A historic San Clemente surf shop is reborn as a hybrid coworking and cybersecurity training center, maximizing real estate and local talent pipelines.

As Privia Health prepares to report its Q3 2026 earnings, the physician enablement giant faces a pivotal test amidst shifting value-based care regulations.

As the Department of War scales uncrewed systems, Somewear Labs' new contract highlights the critical shift toward resilient, multi-network drone communications.

Ontario's upcoming watchdog report on French-language service gaps reveals deep bureaucratic flaws. Can the province fix its frontline delivery model?

As the EU prepares to loosen gene-editing regulations in 2028, a new transatlantic licensing deal merges US CRISPR tech with Belgian AI trait discovery.

A sharp rise in September CUSIP identifier requests points to an unfreezing IPO pipeline and strategic corporate debt issuance ahead of an active fourth quarter.

CytoDyn is pivoting to oncology with its CCR5 inhibitor leronlimab. Upcoming Phase 2 data at ESMO 2026 could determine the biotech's financial survival.

Mission Produce aims to double sales by 2035, but can its massive Calavo Growers integration and shift to prepared foods survive commodity market volatility?

Asahi Kasei Therapeutics begins Phase 2a trials for AIC468, a pioneering RNA-splicing therapy aiming to solve a critical kidney transplant dilemma.

Jack Patterson investigates how a new complimentary orthodontic program in Georgia exposes and bypasses systemic gaps in craniofacial healthcare coverage.

A new three-tier triage framework aims to protect prostate cancer patients from the lethal cardiovascular risks of life-extending hormone therapies.

As AI moves from the cloud to the factory floor, enterprises face a billion-dollar question: how to buy hardware that won't be obsolete in six months.